Register for our free email digests:
Latest From AstraZeneca PLC
GSK returned US rights to the IL-6 blocker to J&J as it prioritizes its pharma portfolio under the leadership of new CEO Walmsley.
In her first address as CEO, Emma Walmsley has shocked the market with a long list of changes for GSK, including a total makeover of the group's pharma unit. As a result, more than 30 R&D programs will be getting the axe and a 2011 commercialization partnership with Johnson & Johnson is on its way to the gallows.
PD-1 inhibitor performance and the intense curiosity around AstraZeneca both for its MYSTIC trial and Soriot's faithfulness to the company are key themes at the half-year mark. Eyes are also on commercial performance for Roche's Ocrevus and Merck's anacetrapib for clarity on whether it has a commercial future.
Navigating Medicare's complicated bundled payment system could be tricky for new class of anemia drugs, the HIF prolyl hydroxylase inhibitors, which may start to reach the market for dialysis patients in 2019.
- Therapeutic Areas
- Metabolic Disorders
- North America
- Parent & Subsidiaries
- Kalypsys Inc.
- Senior Management
John McKearn, PhD, Pres. & CEO
Pratik Shah, PhD, CBO
Paul Grint, MD, Head, Dev. & CMO
- Contact Info
Phone: (858) 754-3300
10420 Wateridge Cir.
San Diego, CA 92121
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.